Bradley G. Somer MD
Medical Oncologist; President, West Cancer Center and Research Institute; Associate Professor of Hematology/Oncology, University of Tennessee Health Science Center, Memphis, TennesseeBiographical Sketch:
Dr. Brad Somer, a medical oncologist in Memphis, Tennessee, is the President of the West Cancer Center and Research Institute, where he has practiced since 2002 after completing his fellowship training in hematology/oncology at the University of Pennsylvania Cancer Center in Philadelphia. He is one of the leaders of the most renowned multi-disciplinary comprehensive cancer center servicing the mid-south. He also serves as an assistant professor of hematology/oncology at the University of Tennessee Health Science Center.
Dr. Somer, is actively involved in clinical research in the gastrointestinal/genitourinary clinical trials program. He also serves on the NCCN panel for kidney cancer.
Dr. Somer earned his medical degree from the Albert Einstein College of Medicine in New York, with a Distinction in Research. He completed his internship and residency at the Hospital of the University of Pennsylvania in Philadelphia. While at the University of Pennsylvania, he served as assistant editor of OncoLink, a leading and award-winning cancer information website. He received his MBA at U Mass Amherst with a healthcare focus in conjunction with the American Association of Physician Leadership.
Positions:
Assistant Professor, Hematology/Oncology, University of Tennessee Health Science Center; Senior Partner, West Clinic, Memphis, Tennessee
Degrees:
MD: Albert Einstein College of Medicine, New York
Postgraduate Training:
Fellowship (hematology/oncology):University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania
Clinical Interests:
Genitourinary cancer
Disclosures
Dr. Somer does not have any disclosures.Recent Contributions to PracticeUpdate:
- Targeted Therapy After Complete Resection of Metastatic Lesions in mRCC
- Interpreting Genomic Data to Identify Sequencing Options
- Remaining Options for Patient Who Has Had Multiple Lines of Therapy
- Dr. Bradley Somer’s Recommended Abstracts: 2015 Genitourinary Cancers Symposium
- Efficacy of Sunitinib in Patients With Metastatic or Unresectable RCC Renal Insufficiency
- Looking Hopeful: Nivolumab for Metastatic Renal Cell Carcinoma
- Nivolumab Has Antitumor Activity and a Manageable Safety Profile in Metastatic RCC
- Stable Patient with Long-Standing RCC and Multiple Prior Therapies
- Local Treatments for Metastases of Renal Cell Carcinoma
- MY APPROACH to Diarrhea Associated With Therapies for Renal Cell Carcinoma